AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 31 min read$IRTC

Rosenbaum Marc Wade sold $79K of IRTC

Rosenbaum Marc Wade (Chief Accounting Officer) sold 729 shares of iRhythm Holdings, Inc. (IRTC) at $108.19 on 2026-06-02.

Original reporting
SEC EDGAR · Rosenbaum Marc Wade
Published Jun 3, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 8:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

The disclosure updates the insider-trading record but does not introduce new operational or financial information about IRTC.

02

Market read

Traders may monitor for clustering of insider sales, but this single transaction alone is unlikely to drive a major repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context (e.g., options exercises, compensation timing), directional inference is weak.

Relevance 6/10Novelty 6/10Timing: Filed after-hours on 2026-06-03; reflects sale dated 2026-06-02.

Background

The filing is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

SEC Form 4 shows Chief Accounting Officer Marc Wade sold 729 shares of iRhythm Holdings on 2026-06-02 at ~$108.19.

Expected impact

Likely limited near-term price impact; treat as low-signal unless repeated or paired with other negative disclosures.

Evidence & confidence

The article provides only an insider transaction datapoint (no 10b5-1 plan, no earnings/guidance/litigation update), which typically has modest standalone market impact.

Market effects

Sector

Minimal; this is company-specific insider activity with no stated sector-wide trigger.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale was not under a 10b5-1 plan, some traders may read it as a stronger signal than routine planned selling—watch for follow-on sales or other insider actions.

Key entities

  • issuer
    iRhythm Holdings, Inc.

    Subject of the SEC Form 4 insider transaction; officer sold shares on 2026-06-02.

  • insider
    Marc Wade Rosenbaum

    Chief Accounting Officer who executed the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

IRTC insider trading history →

Related articles

OCT 5
$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

investing.com2 min
OCT 5
$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

SEC EDGAR 8-K2 min
OCT 5
$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.

globenewswire.com3 min
SEP 22
$IRTCMedAI 8/10

IRhythm Holdings, Inc., a Delaware corporation, iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01. Regulation FD Disclosure. As previously announced, on August 5, 2026, iRhythm Holdings, Inc., a Delaware corporation (the “Company”), iRhythm Technologies, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Acquirer”), Project Vessel Mer

SEC EDGAR 8-K1 min